Annual and transition report of foreign private issuers pursuant to Section 13 or 15(d)

Consolidated Statements of Comprehensive Loss

v3.23.1
Consolidated Statements of Comprehensive Loss - CAD ($)
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Expenses      
Amortization $ 75,268 $ 17,882 $ 20,439
Consulting 309,156 724,272 102,880
Directors' fees 161,054 62,200  
General and administrative 582,192 176,099 9,516
Investor relations 1,200,318 518,615 241,177
Listing fees 157,200 236,801 52,138
Professional fees 587,851 272,943 162,580
Research and development 8,807,992 853,124 277,455
Share-based payments 632,548 499,158 293,443
Travel 29,668 2,339 8,460
Wages and benefits 841,804 286,090 227,905
Loss before other items (13,385,051) (3,649,523) (1,395,993)
Accretion     (846)
Fair value adjustment on derivative warrant liability 4,470,276 3,299,768  
Foreign exchange gain 549,637 326,751 2,961
Forgiveness of debt     91,014
Interest income (expense) 137,575 (5,598) (12,666)
Impairment of intangible assets     (64,562)
Recovery of provision for patent acquisition     95,490
Transaction costs on derivative warrant liability (1,257,746) (1,623,680)  
Net loss and comprehensive loss for the year $ (9,485,309) $ (1,652,282) $ (1,284,602)
Basic and diluted loss per common share      
Basic loss per common share $ (0.71) $ (0.17) $ (0.19)
Diluted loss per common share $ (0.71) $ (0.17) $ (0.19)
Weighted average number of common shares outstanding      
Weighted average number of common shares outstanding, Basic 13,319,226 9,847,641 6,664,025
Weighted average number of common shares outstanding, Diluted 13,319,226 9,847,641 6,664,025